These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 3315596)
1. Treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex in a district hospital. Efficacy data. Chamberlain DA Drugs; 1987; 33 Suppl 3():221-2. PubMed ID: 3315596 [No Abstract] [Full Text] [Related]
2. Treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex in a district hospital. Tolerance data. Chamberlain DA Drugs; 1987; 33 Suppl 3():286. PubMed ID: 3315609 [No Abstract] [Full Text] [Related]
3. Evaluation of the efficacy and safety of anisoylated plasminogen streptokinase activator complex in early myocardial infarction. Preliminary results. Lenhoff SJ; Horak AR; Fraser RC; Scott-Millar RN; Bird AR; Jacobs P; Commerford PJ Drugs; 1987; 33 Suppl 3():186-8. PubMed ID: 3315590 [No Abstract] [Full Text] [Related]
4. Safety and side effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study. Monassier JP; Hanssen M Drugs; 1987; 33 Suppl 3():282-5. PubMed ID: 3315608 [TBL] [Abstract][Full Text] [Related]
5. Comparative tolerance and complications in a multicentre trial of intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. Rothbard RL Drugs; 1987; 33 Suppl 3():276-8. PubMed ID: 3315606 [TBL] [Abstract][Full Text] [Related]
6. Tolerance and complications in a multicenter trial of intravenous APSAC and intracoronary streptokinase in acute myocardial infarction. Rothbard RL; Anderson JL; Fitzpatrick PG; Hakworthy RA; Sorensen SG; Marder VJ Clin Cardiol; 1990 Mar; Suppl 5():V11-4; discussion V27-32. PubMed ID: 2182234 [TBL] [Abstract][Full Text] [Related]
7. Anistreplase for acute coronary thrombosis. Med Lett Drugs Ther; 1990 Feb; 32(812):15-6. PubMed ID: 2406552 [No Abstract] [Full Text] [Related]
9. Summary of early clinical experience with anisoylated plasminogen streptokinase activator complex in the treatment of acute myocardial infarction. Jackson D Drugs; 1987; 33 Suppl 3():104-11. PubMed ID: 3315574 [TBL] [Abstract][Full Text] [Related]
10. Acylated plasminogen-streptokinase activator complex: a new approach to thrombolytic therapy. Crabbe SJ; Grimm AM; Hopkins LE Pharmacotherapy; 1990; 10(2):115-26. PubMed ID: 2140889 [TBL] [Abstract][Full Text] [Related]
11. Anisoylated plasminogen streptokinase activator complex versus placebo. A preliminary multicentre study of safety and early mortality in acute myocardial infarction. Julian DG; Borthwick LS; Reid D; Jennings KP; Wainwright RJ; Rodger JC; Wood D; Phillips WS Drugs; 1987; 33 Suppl 3():261-7. PubMed ID: 3315604 [TBL] [Abstract][Full Text] [Related]
12. A placebo-controlled patency study of intravenous anisoylated plasminogen streptokinase activator complex 30U in acute myocardial infarction. de Bono DP Drugs; 1987; 33 Suppl 3():138-9. PubMed ID: 3315580 [No Abstract] [Full Text] [Related]
14. An interim report of the efficacy and safety of anisoylated plasminogen streptokinase activator complex (APSAC). Johnson ES; Cregeen RJ Drugs; 1987; 33 Suppl 3():298-311. PubMed ID: 3315612 [TBL] [Abstract][Full Text] [Related]
15. Comparison of intravenous anisoylated plasminogen streptokinase activator complex and intracoronary streptokinase in acute myocardial infarction. Bonnier HJ; Visser RF; Klomps HC; Hoffmann HJ Am J Cardiol; 1988 Jul; 62(1):25-30. PubMed ID: 3289357 [TBL] [Abstract][Full Text] [Related]
16. Early clinical evaluation of the intravenous treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex. Kasper W; Meinertz T; Wollschläger H; Bonzel T; Chen C; Hofmann T; Zeiher A; Drexler H; Just H Drugs; 1987; 33 Suppl 3():112-6. PubMed ID: 3315575 [TBL] [Abstract][Full Text] [Related]
17. Intravenous fibrinolytic therapy of acute myocardial infarction: new perspectives from plasminogen activators? Kasper W; Meinertz T; Just H Klin Wochenschr; 1986 Apr; 64(7):301-6. PubMed ID: 3086619 [TBL] [Abstract][Full Text] [Related]
18. Vasculitis complicating treatment with intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. Gemmill JD; Sandler M; Hillis WS; Tillman J; Wakeel R Br Heart J; 1988 Oct; 60(4):361. PubMed ID: 3056478 [No Abstract] [Full Text] [Related]
19. Reperfusion in acute myocardial infarction. A multicentre randomised trial of early intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in the United States. Anderson JL Drugs; 1987; 33 Suppl 3():154-62. PubMed ID: 3315584 [TBL] [Abstract][Full Text] [Related]
20. AIMS. The design and conduct of a multicentre mortality study comparing placebo and anisoylated plasminogen streptokinase activator complex 30 units intravenously for the treatment of acute myocardial infarction of less than 6 hours duration. UK APSAC Advisory Committee. Drugs; 1987; 33 Suppl 3():227-8. PubMed ID: 3315598 [No Abstract] [Full Text] [Related] [Next] [New Search]